Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants Pfizer’s Lorlatinib breakthrough designation for NSCLC
Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicine
Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicine
Ezetimibe and simvastatin tablets are a prescription medicine that contains two cholesterol lowering medicines, ezetimibe and simvastatin, which are used along with diet to: Lower the level of
Several additional new investors participated in the financing, including GV (formerly Google Ventures) and Alexandria Venture Investments. The company’s existing investors, including OrbiMed, Polaris Venture Partners, SV Health
This designation is based on results from the ongoing, dose-ranging Phase 1-2 study that show a near cessation of spontaneous bleeding in patients with severe disease at up
The round included new strategic investments from Amgen Ventures, as well as participation from all existing investors Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint
Clinical cure was the primary endpoint of the study and defined as a complete resolution of all signs and symptoms of infection. In addition, patients treated with Zavicefta
Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor. Elias Zerhouni, M.D., President, Global R&D, Sanofi said: “Rheumatoid arthritis is a painful and debilitating disease
NGM282, which is a non-tumorigenic, engineered variant of the human hormone FGF19, demonstrated a significant reduction in liver fat content and improvement of biomarkers associated with the resolution
Mark Levick, MD PhD, Global Head of Development, Biopharmaceuticals, Sandoz, said: "We are proud to help patients in Europe with blood cancers and immunological diseases by improving their
H3 and Foundation Medicine will continue to build upon the progress the two companies have made during the collaboration. The companies will collaborate to interrogate the FoundationCORE dataset,